244239-39-2

Upstream product

• 264271-57-0 methyl (αS,3S)-13-azido-α-[[4-[(3-methyl-2-butenyl)oxy]phenyl]methyl]-12-oxo-1,6-dioxa-11-azadispiro[4.2.6.2]hexadecane-11-acetate 
• 264271-71-8 Formic acid (S)-2-((S)-3-formylamino-9,14-dioxa-1-aza-dispiro[4.2.6.2]hexadec-1-yl)-3-[4-(3-methyl-but-2-enyloxy)-phenyl]-propyl ester 
• 264271-70-7 (S)-2-((S)-3-Amino-9,14-dioxa-1-aza-dispiro[4.2.6.2]hexadec-1-yl)-3-[4-(3-methyl-but-2-enyloxy)-phenyl]-propan-1-ol 
• 264271-58-1 (S)-2-((S)-3-Methylamino-9,14-dioxa-1-aza-dispiro[4.2.6.2]hexadec-1-yl)-3-[4-(3-methyl-but-2-enyloxy)-phenyl]-propan-1-ol 
• 264271-61-6 C₂₈H₃₉N₂O₃⁽¹⁺⁾ 
• 264271-60-5 (5S)-4-methyl-2-[[4-[(3-methyl-2-butenyl)oxy]phenyl]methyl]-dispiro[1,4-diazabicyclo[3.2.1]oct[2]en-7,1'-cyclohexane-4',2-[1,3]dioxepane] 
• 338386-44-0 C₂₆H₃₄N₂O₄ 
• 752206-21-6 4-(tert-butyl-dimethyl-silanyloxy)-2-formyl-2-(3-oxo-butyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 752206-19-2 2-(4-bromo-3-methyl-but-3-enyl)-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 752206-15-8 3-(tert-butyl-dimethyl-silanyloxy)-7-methyl-1-aza-spiro[4.4]non-6-ene-1-carboxylic acid tert-butyl ester 
• 752206-18-1 4-(tert-butyl-dimethyl-silanyloxy)-2-(3-oxo-butyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 752206-23-8 3-methanesulfonyloxy-8-oxo-1-aza-spiro[4.5]decane-1-carboxylic acid tert-butyl ester 
• 752206-16-9 (3R,5R)-3-Methanesulfonyloxy-8-oxo-1-aza-spiro[4.5]dec-6-ene-1-carboxylic acid tert-butyl ester 
• 752206-24-9 3-azido-8-oxo-1-aza-spiro[4.5]decane-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

An enantioselective formal total synthesis of (-)-TAN1251A

An enantioselective total synthesis of the muscarinic inhibitor (-)-TAN1251A has been achieved. An alkylidene 1,5-CH insertion reaction was used as a key step to produce a [5,5]-spirocyclic intermediate, which was transformed into the [6,5]-spirocyclic co

Biomimetic total syntheses of (-)-TAN1251A, (+)-TAN1251B, (+)-TAN1251C, and (+)-TAN1251D

(equation presented) The muscarinic antagonists (-)-TAN1251A (1), (+)-TAN1251B (2), (+)-TAN1251C (3), and (+)-TAN1251D (4) have been synthesized biomimetically by enamine formation from an amino aldehyde to give TAN1251C ketal 18. Oxidation and reduction lead to TAN1251A (1), which has been hydroxylated to give TAN1251B (2). Stereospecific reduction of TAN1251C ketal 18 leads to TAN1251D (4).